ghk-cu clinical trial wound healing randomized double blind Rigid-flexible nanocarriers loaded with active peptides for antioxidant and anti-inflammatory applications in skin GHK-Cu 2026: Benefits, Mechanisms, Safety

In its lawsuit, the OFA said that the FDAs decision to end the shortage was a reckless and arbitrary move and could deprive patients of a vital treatment for type 2 diabetes and obesity. In an interview with BioSpace last month, David Rosen, partner at Foley & Lardner, said that the lawsuit is a precedent in this area. Prior to the OFA suit, no one has ever challenged the FDAs decision to remove a therapy from the drug shortage list. The OFA case is still ongoing, with the next court update due on Thursday

10.1038/327239a0 Nature 175 SufitR

Slow wound healing and irritation of the skin

For chronic social anxiety, twice-daily dosing of 12-20 IU may provide sustained benefits